{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:56:07Z","timestamp":1793145367156,"version":"4.5.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03246-1","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T02:33:25Z","timestamp":1770604405000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hippo-YAP\/TAZ signaling in gastric cancer: molecular pathogenesis and emerging therapeutic horizons"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3575-2873","authenticated-orcid":false,"given":"Mandeep","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel Fabian","family":"Mungurere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Mitinje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopal Krishna","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arora Sukhpreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"3246_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1136\/gutjnl-2024-333227","volume":"74","author":"P Danpanichkul","year":"2025","unstructured":"Danpanichkul P, Suparan K, Tothanarungroj P, et al. Epidemiology of gastrointestinal cancers: A systematic analysis from the global burden of disease study 2021. Gut. 2025;74:26\u201334.","journal-title":"Gut"},{"key":"3246_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5114\/pg.2018.80001","volume":"14","author":"P Rawla","year":"2019","unstructured":"Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Gastroenterol Rev Gastroenterol. 2019;14:26\u201338.","journal-title":"Gastroenterol Rev Gastroenterol"},{"key":"3246_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01442-3","volume":"8","author":"M You","year":"2023","unstructured":"You M, Xie Z, Zhang N, et al. Signaling pathways in cancer metabolism: mechanisms and therapeutic targets. Signal Transduct Target Ther. 2023;8:196. https:\/\/doi.org\/10.1038\/s41392-023-01442-3.","journal-title":"Signal Transduct Target Ther"},{"key":"3246_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22:138.","journal-title":"Mol Cancer"},{"key":"3246_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13045-020-00990-3","volume":"13","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Wang X. Targeting the Wnt\/\u03b2-catenin signaling pathway in cancer. J Hematol Oncol. 2020;13:165.","journal-title":"J Hematol Oncol"},{"key":"3246_CR6","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.cell.2015.10.044","volume":"163","author":"FX Yu","year":"2015","unstructured":"Yu FX, Zhao B, Guan KL. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell. 2015;163:811\u201328.","journal-title":"Cell"},{"key":"3246_CR7","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.230425","volume":"133","author":"A Pocaterra","year":"2020","unstructured":"Pocaterra A, Romani P, Dupont S. Yap\/TAZ functions and their regulation at a glance. J Cell Sci. 2020;133:jcs230425.","journal-title":"J Cell Sci"},{"key":"3246_CR8","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.cell.2005.06.007","volume":"122","author":"J Huang","year":"2005","unstructured":"Huang J, Wu S, Barrera J, et al. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating yorkie, the Drosophila homolog of YAP. Cell. 2005;122:421\u201334.","journal-title":"Cell"},{"key":"3246_CR9","first-page":"9","volume":"4","author":"S Piccolo","year":"2023","unstructured":"Piccolo S, Panciera T, Contessotto P, et al. YAP\/TAZ as master regulators in cancer: modulation, function, and therapeutic approaches. Nat Cancer. 2023;4:9\u201326.","journal-title":"Nat Cancer"},{"key":"3246_CR10","doi-asserted-by":"publisher","first-page":"5798","DOI":"10.1111\/febs.16091","volume":"289","author":"H Kwon","year":"2022","unstructured":"Kwon H, Kim J, Jho E. Role of the Hippo pathway and mechanisms for controlling cellular localization of YAP\/TAZ. FEBS J. 2022;289:5798\u2013818.","journal-title":"FEBS J"},{"key":"3246_CR11","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41573-020-0070-z","volume":"19","author":"A Dey","year":"2020","unstructured":"Dey A, Varelas X, Guan KL. Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat Rev Drug Discov. 2020;19:480\u201394.","journal-title":"Nat Rev Drug Discov"},{"key":"3246_CR12","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.3390\/cancers15133468","volume":"15","author":"RB Mokhtari","year":"2023","unstructured":"Mokhtari RB, Ashayeri N, Baghaie L, et al. The hippo pathway effectors YAP\/TAZ-TEAD oncoproteins as emerging therapeutic targets in the tumor microenvironment. Cancers (Basel). 2023;15:3468.","journal-title":"Cancers (Basel)"},{"key":"3246_CR13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1042\/CS20201474","volume":"136","author":"R Cunningham","year":"2022","unstructured":"Cunningham R, Hansen CG. The Hippo pathway in cancer: YAP\/TAZ and TEAD as therapeutic targets in cancer. Clin Sci. 2022;136:197\u2013222.","journal-title":"Clin Sci"},{"key":"3246_CR14","doi-asserted-by":"publisher","first-page":"6216","DOI":"10.7150\/jca.62402","volume":"12","author":"M Wang","year":"2021","unstructured":"Wang M, Dai M, Wang D, et al. The regulatory networks of the Hippo signaling pathway in cancer development. J Cancer. 2021;12:6216.","journal-title":"J Cancer"},{"key":"3246_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1595362","volume":"13","author":"J Zhang","year":"2025","unstructured":"Zhang J, Wu H, Ren X, et al. Hippo\/YAP signaling\u2019s multifaceted crosstalk in cancer. Front Cell Dev Biol. 2025;13:1595362.","journal-title":"Front Cell Dev Biol"},{"key":"3246_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fcell.2019.00049","volume":"7","author":"GTK Boopathy","year":"2019","unstructured":"Boopathy GTK, Hong W. Role of hippo pathway-YAP\/TAZ signaling in angiogenesis. Front Cell Dev Biol. 2019;7:49.","journal-title":"Front Cell Dev Biol"},{"key":"3246_CR17","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3389\/fcell.2020.00735","volume":"8","author":"BC Heng","year":"2020","unstructured":"Heng BC, Zhang X, Aubel D, et al. Role of YAP\/TAZ in cell lineage fate determination and related signaling pathways. Front Cell Dev Biol. 2020;8:735.","journal-title":"Front Cell Dev Biol"},{"key":"3246_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2020.109858","volume":"78","author":"P Samji","year":"2021","unstructured":"Samji P, Rajendran MK, Warrier VP, et al. Regulation of Hippo signaling pathway in cancer: A MicroRNA perspective. Cell Signal. 2021;78:109858.","journal-title":"Cell Signal"},{"key":"3246_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.semcancer.2021.07.006","volume":"85","author":"FL Li","year":"2022","unstructured":"Li FL, Guan KL. The two sides of Hippo pathway in cancer. Semin Cancer Biol Elsevier. 2022;85:33\u201342.","journal-title":"Semin Cancer Biol Elsevier"},{"key":"3246_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092282","volume":"14","author":"L Seeneevassen","year":"2022","unstructured":"Seeneevassen L, Dubus P, Gronnier C, et al. Hippo in gastric cancer: from signalling to therapy. Cancers (Basel). 2022;14:2282.","journal-title":"Cancers (Basel)"},{"key":"3246_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-024-00331-8","volume":"44","author":"A Nita","year":"2024","unstructured":"Nita A, Moroishi T. Hippo pathway in cell-cell communication: emerging roles in development and regeneration. Inflamm Regen. 2024;44:18. https:\/\/doi.org\/10.1186\/s41232-024-00331-8.","journal-title":"Inflamm Regen"},{"key":"3246_CR22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1159\/000507538","volume":"16","author":"A Kyriazoglou","year":"2021","unstructured":"Kyriazoglou A, Liontos M, Zakopoulou R, et al. The role of the Hippo pathway in breast cancer carcinogenesis, prognosis, and treatment: A systematic review. Breast Care. 2021;16:6\u201315.","journal-title":"Breast Care"},{"key":"3246_CR23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1071\/CH22241","volume":"76","author":"Z Huang","year":"2023","unstructured":"Huang Z, Tan Y, Zhang W, et al. Hippo signaling in cancer: regulatory mechanisms and therapeutic strategies. Aust J Chem. 2023;76:399\u2013412.","journal-title":"Aust J Chem"},{"key":"3246_CR24","doi-asserted-by":"crossref","unstructured":"Gokhale R, Pfleger CM. The power of drosophila genetics: the discovery of the hippo pathway. Hippo Pathw Methods Protoc; 2018. pp. 3\u201326.","DOI":"10.1007\/978-1-4939-8910-2_1"},{"key":"3246_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cells11081370","volume":"11","author":"F Faraji","year":"2022","unstructured":"Faraji F, Ramirez SI, Anguiano Quiroz PY, et al. Genomic hippo pathway alterations and persistent YAP\/TAZ activation: new hallmarks in head and neck cancer. Cells. 2022;11:1370.","journal-title":"Cells"},{"key":"3246_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15235497","volume":"15","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Sheldon M, Sun Y, et al. New insights into YAP\/TAZ-TEAD-mediated gene regulation and biological processes in cancer. Cancers (Basel). 2023;15:5497.","journal-title":"Cancers (Basel)"},{"key":"3246_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrc3876","volume":"15","author":"T Moroishi","year":"2015","unstructured":"Moroishi T, Hansen CG, Guan KL. The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 2015;15:73\u20139.","journal-title":"Nat Rev Cancer"},{"key":"3246_CR28","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.canlet.2019.12.044","volume":"473","author":"SME Weiler","year":"2020","unstructured":"Weiler SME, Lutz T, Bissinger M, et al. TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells. Cancer Lett. 2020;473:164\u201375.","journal-title":"Cancer Lett"},{"key":"3246_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.673599","volume":"9","author":"X Cai","year":"2021","unstructured":"Cai X, Wang KC, Meng Z. Mechanoregulation of YAP and TAZ in cellular homeostasis and disease progression. Front Cell Dev Biol. 2021;9:673599.","journal-title":"Front Cell Dev Biol"},{"key":"3246_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12862-025-02378-8","volume":"25","author":"EP Ahi","year":"2025","unstructured":"Ahi EP, Panda B, Primmer CR. The hippo pathway: A molecular bridge between environmental cues and pace of life. BMC Ecol Evol. 2025;25:35.","journal-title":"BMC Ecol Evol"},{"key":"3246_CR31","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3389\/fonc.2020.00928","volume":"10","author":"H Yamaguchi","year":"2020","unstructured":"Yamaguchi H, Taouk GM. A potential role of YAP\/TAZ in the interplay between metastasis and metabolic alterations. Front Oncol. 2020;10:928.","journal-title":"Front Oncol"},{"key":"3246_CR32","first-page":"347","volume":"9","author":"NH Lee","year":"2021","unstructured":"Lee NH, Kim SJ, Hyun J. MicroRNAs regulating Hippo-YAP signaling in liver cancer. Biomed. 2021;9:347.","journal-title":"Biomed"},{"key":"3246_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/gad.274027.115","volume":"30","author":"Z Meng","year":"2016","unstructured":"Meng Z, Moroishi T, Guan K-L. Mechanisms of Hippo pathway regulation. Genes Dev. 2016;30:1\u201317.","journal-title":"Genes Dev"},{"key":"3246_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/bies.201900162","volume":"42","author":"BJ Thompson","year":"2020","unstructured":"Thompson BJ. YAP\/TAZ: drivers of tumor growth, metastasis, and resistance to therapy. BioEssays. 2020;42:1900162.","journal-title":"BioEssays"},{"key":"3246_CR35","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.devcel.2019.06.003","volume":"50","author":"Y Zheng","year":"2019","unstructured":"Zheng Y, Pan D. The hippo signaling pathway in development and disease. Dev Cell. 2019;50:264\u201382.","journal-title":"Dev Cell"},{"key":"3246_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2021.119201","volume":"1869","author":"U Lee","year":"2022","unstructured":"Lee U, Cho EY, Jho EH. Regulation of Hippo signaling by metabolic pathways in cancer. Biochimica et Biophysica Acta (BBA). 2022;1869:119201.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"3246_CR37","doi-asserted-by":"publisher","first-page":"756","DOI":"10.3390\/cancers13040756","volume":"13","author":"B Zhu","year":"2021","unstructured":"Zhu B, V M, Finch-Edmondson M, et al. miR-582-5p is a tumor suppressor microRNA targeting the Hippo-YAP\/TAZ signaling pathway in non-small cell lung cancer. Cancers (Basel). 2021;13:756.","journal-title":"Cancers (Basel)"},{"key":"3246_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01191-9","volume":"7","author":"M Fu","year":"2022","unstructured":"Fu M, Hu Y, Lan T, et al. The Hippo signalling pathway and its implications in human health and diseases. Signal Transduct Target Ther. 2022;7:376.","journal-title":"Signal Transduct Target Ther"},{"key":"3246_CR39","volume":"10","author":"X Liu","year":"2022","unstructured":"Liu X, Wang Y, Chen B, et al. Targeting the hippo pathway in gastric cancer and other malignancies in the digestive system: from bench to bedside. Biomed. 2022;10:2512.","journal-title":"Biomed"},{"key":"3246_CR40","doi-asserted-by":"publisher","first-page":"658481","DOI":"10.3389\/fcell.2021.658481","volume":"9","author":"YS Cho","year":"2021","unstructured":"Cho YS, Jiang J. Hippo-independent regulation of Yki\/Yap\/Taz: A non-canonical view. Front Cell Dev Biol. 2021;9:658481.","journal-title":"Front Cell Dev Biol"},{"key":"3246_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay8798","volume":"12","author":"S Alsamman","year":"2020","unstructured":"Alsamman S, Christenson SA, Yu A, et al. Targeting acid ceramidase inhibits YAP\/TAZ signaling to reduce fibrosis in mice. Sci Transl Med. 2020;12:eaay8798.","journal-title":"Sci Transl Med"},{"key":"3246_CR42","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2022111549","volume":"42","author":"B Yuan","year":"2023","unstructured":"Yuan B, Liu J, Shi A, et al. HERC3 promotes YAP\/TAZ stability and tumorigenesis independently of its ubiquitin ligase activity. EMBO J. 2023;42:e111549.","journal-title":"EMBO J"},{"key":"3246_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16213605","volume":"16","author":"C Palanivel","year":"2024","unstructured":"Palanivel C, Somers TN, Gabler BM, et al. Rac1 GTPase regulates the \u03b2TrCP-mediated proteolysis of YAP independently of the LATS1\/2 kinases. Cancers (Basel). 2024;16:3605.","journal-title":"Cancers (Basel)"},{"key":"3246_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62566-4","volume":"16","author":"G Zhao","year":"2025","unstructured":"Zhao G, Luo S, Zhao H, et al. Nucleus-translocated glucokinase functions as a protein kinase to phosphorylate TAZ and promote tumour growth. Nat Commun. 2025;16:7156.","journal-title":"Nat Commun"},{"key":"3246_CR45","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12967-019-1869-4","volume":"17","author":"Y Han","year":"2019","unstructured":"Han Y. Analysis of the role of the hippo pathway in cancer. J Transl Med. 2019;17:116.","journal-title":"J Transl Med"},{"key":"3246_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164242","volume":"13","author":"A Lopez-Hernandez","year":"2021","unstructured":"Lopez-Hernandez A, Sberna S, Campaner S. Emerging principles in the transcriptional control by YAP and TAZ. Cancers (Basel). 2021;13:4242.","journal-title":"Cancers (Basel)"},{"key":"3246_CR47","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3390\/ijms23010430","volume":"23","author":"\u00c1 Ortega","year":"2021","unstructured":"Ortega \u00c1, Vera I, Diaz MP, et al. The YAP\/TAZ signaling pathway in the tumor microenvironment and carcinogenesis: current knowledge and therapeutic promises. Int J Mol Sci. 2021;23:430.","journal-title":"Int J Mol Sci"},{"key":"3246_CR48","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jhep.2021.08.021","volume":"76","author":"H Wang","year":"2022","unstructured":"Wang H, Zhang S, Zhang Y, et al. TAZ is indispensable for c-MYC-induced hepatocarcinogenesis. J Hepatol. 2022;76:123\u201334.","journal-title":"J Hepatol"},{"key":"3246_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061462","volume":"9","author":"C Tiffon","year":"2020","unstructured":"Tiffon C, Giraud J, Molina-Castro SE, et al. TAZ controls Helicobacter pylori-induced epithelial\u2013mesenchymal transition and cancer stem cell-like invasive and tumorigenic properties. Cells. 2020;9:1462.","journal-title":"Cells"},{"key":"3246_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.612802","volume":"10","author":"A Hooglugt","year":"2021","unstructured":"Hooglugt A, Van der Stoel MM, Boon RA, et al. Endothelial YAP\/TAZ signaling in angiogenesis and tumor vasculature. Front Oncol. 2021;10:612802.","journal-title":"Front Oncol"},{"key":"3246_CR51","first-page":"893","volume":"55","author":"Z Cao","year":"2023","unstructured":"Cao Z, An L, Han Y, et al. The Hippo signaling pathway in gastric cancer: targeting Hippo for GC treatment. Acta Biochim Biophys Sin (Shanghai). 2023;55:893.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"3246_CR52","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12964-023-01396-7","volume":"22","author":"KM Choi","year":"2024","unstructured":"Choi KM, Kim B, Lee SM, et al. Characterization of gastric cancer-stimulated signaling pathways and function of CTGF in cancer-associated fibroblasts. Cell Commun Signal. 2024;22:8.","journal-title":"Cell Commun Signal"},{"key":"3246_CR53","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1159\/000536507","volume":"42","author":"L Ma","year":"2024","unstructured":"Ma L, Gao F, Dong W, et al. Association study between SNPs in MST1 and MST2 and H. pylori infection as well as noncardia gastric carcinogenesis. Dig Dis. 2024;42:230\u20139.","journal-title":"Dig Dis"},{"key":"3246_CR54","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00432-021-03552-3","volume":"147","author":"\u00cdSS de Amorim","year":"2021","unstructured":"de Amorim \u00cdSS, de Sousa Rodrigues MM, Mencalha AL. The tumor suppressor role of salvador family WW domain-containing protein 1 (SAV1): one of the key pieces of the tumor puzzle. J Cancer Res Clin Oncol. 2021;147:1287\u201397.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3246_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05027-8","volume":"22","author":"G Schiavoni","year":"2024","unstructured":"Schiavoni G, Messina B, Scalera S, et al. Role of Hippo pathway dysregulation from gastrointestinal premalignant lesions to cancer. J Transl Med. 2024;22:213.","journal-title":"J Transl Med"},{"key":"3246_CR56","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.gendis.2020.05.004","volume":"8","author":"T Sun","year":"2021","unstructured":"Sun T, Chi JT. Regulation of ferroptosis in cancer cells by YAP\/TAZ and Hippo pathways: the therapeutic implications. Genes Dis. 2021;8:241\u20139.","journal-title":"Genes Dis"},{"key":"3246_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2025.1631168","volume":"12","author":"Y Yin","year":"2025","unstructured":"Yin Y, Zeng S, Zhang H, et al. Patient-derived gastric cancer organoids model heterogeneity and stroma-mediated chemoresistance in poorly cohesive carcinoma. Front Mol Biosci. 2025;12:1631168.","journal-title":"Front Mol Biosci"},{"key":"3246_CR58","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1186\/s12885-023-11434-9","volume":"23","author":"J Gao","year":"2023","unstructured":"Gao J, Lan J, Liao H, et al. Promising preclinical patient-derived organoid (PDO) and xenograft (PDX) models in upper gastrointestinal cancers: progress and challenges. BMC Cancer. 2023;23:1205.","journal-title":"BMC Cancer"},{"key":"3246_CR59","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s10120-024-01548-9","volume":"27","author":"M Kanda","year":"2024","unstructured":"Kanda M, Takano N, Miyauchi H, et al. Preclinical toxicological assessment of amido-bridged nucleic acid-modified antisense oligonucleotides targeting synaptotagmin XIII for intra-abdominal treatment of peritoneal metastasis of gastric cancer. Gastric Cancer. 2024;27:1229\u201341.","journal-title":"Gastric Cancer"},{"key":"3246_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00895-9","volume":"9","author":"C Deng","year":"2025","unstructured":"Deng C, Xie C, Li Z, et al. Multi-omics analysis identifies diagnostic circulating biomarkers and potential therapeutic targets, revealing IQGAP1 as an oncogene in gastric cancer. NPJ Precis Oncol. 2025;9:105.","journal-title":"NPJ Precis Oncol"},{"key":"3246_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242316931","volume":"24","author":"O Repetto","year":"2023","unstructured":"Repetto O, Vettori R, Steffan A, et al. Circulating proteins as diagnostic markers in gastric cancer. Int J Mol Sci. 2023;24:16931.","journal-title":"Int J Mol Sci"},{"key":"3246_CR62","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1245\/s10434-024-16845-x","volume":"32","author":"M Shinkai","year":"2025","unstructured":"Shinkai M, Imano M, Yokokawa M, et al. Phase I\/II study of neoadjuvant chemoradiotherapy consisting of S-1 and cisplatin for patients with clinically resectable type 4 or large type 3 gastric cancer (OGSG1205). Ann Surg Oncol. 2025;32:2651\u201361.","journal-title":"Ann Surg Oncol"},{"key":"3246_CR63","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1111\/cas.16110","volume":"115","author":"S Zhao","year":"2024","unstructured":"Zhao S, Su L, Huang F, et al. Phase I trial of apatinib and paclitaxel+ oxaliplatin+ 5\u2010FU\/levoleucovorin for treatment\u2010na\u00efve advanced gastric cancer. Cancer Sci. 2024;115:1611\u201321.","journal-title":"Cancer Sci"},{"key":"3246_CR64","volume":"14","author":"C Trejo-Solis","year":"2021","unstructured":"Trejo-Solis C, Escamilla-Ramirez A, Jimenez-Farfan D, et al. Crosstalk of the Wnt\/\u03b2-catenin signaling pathway in the induction of apoptosis on cancer cells. Pharma. 2021;14:871.","journal-title":"Pharma"},{"key":"3246_CR65","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1038\/s41417-020-00281-6","volume":"28","author":"SE Lamhamedi-Cherradi","year":"2021","unstructured":"Lamhamedi-Cherradi SE, Mohiuddin S, Mishra DK, et al. Transcriptional activators YAP\/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma. Cancer Gene Ther. 2021;28:1325\u201338.","journal-title":"Cancer Gene Ther"},{"key":"3246_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/wdev.371","volume":"9","author":"BJ van Soldt","year":"2020","unstructured":"van Soldt BJ, Cardoso WV. Hippo\u2010Yap\/Taz signaling: complex network interactions and impact in epithelial cell behavior. Wiley Interdiscip Rev Dev Biol. 2020;9:e371.","journal-title":"Wiley Interdiscip Rev Dev Biol"},{"key":"3246_CR67","first-page":"37","volume-title":"YAP\/TAZ-mediated resistance to EGFR inhibitors","author":"H Yamaguchi","year":"2023","unstructured":"Yamaguchi H, Taouk GM. YAP\/TAZ-mediated resistance to EGFR inhibitors. Overcoming Resist. to EGFR Inhib. EGFR-Mutant NSCLC: Elsevier; 2023. p. 37\u201353."},{"key":"3246_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114847","volume":"244","author":"M Luo","year":"2022","unstructured":"Luo M, Xu Y, Chen H, et al. Advances of targeting the YAP\/TAZ-TEAD complex in the hippo pathway for the treatment of cancers. Eur J Med Chem. 2022;244:114847.","journal-title":"Eur J Med Chem"},{"key":"3246_CR69","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s00432-021-03604-8","volume":"147","author":"H-L Li","year":"2021","unstructured":"Li H-L, Li Q-Y, Jin M-J, et al. A review: hippo signaling pathway promotes tumor invasion and metastasis by regulating target gene expression. J Cancer Res Clin Oncol. 2021;147:1569\u201385.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3246_CR70","first-page":"4399","volume":"10","author":"A Kaneda","year":"2020","unstructured":"Kaneda A, Seike T, Danjo T, et al. The novel potent TEAD inhibitor, K-975, inhibits YAP1\/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma. Am J Cancer Res. 2020;10:4399.","journal-title":"Am J Cancer Res"},{"key":"3246_CR71","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.80210","volume":"11","author":"L Hu","year":"2022","unstructured":"Hu L, Sun Y, Liu S, et al. Discovery of a new class of reversible TEA domain transcription factor inhibitors with a novel binding mode. Elife. 2022;11:e80210.","journal-title":"Elife"},{"key":"3246_CR72","doi-asserted-by":"publisher","first-page":"CT006","DOI":"10.1158\/1538-7445.AM2023-CT006","volume":"83","author":"TA Yap","year":"2023","unstructured":"Yap TA, Kwiatkowski DJ, Desai J, et al. Abstract CT006: first-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)\/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations. Cancer Res. 2023;83:CT006\u2013CT006.","journal-title":"Cancer Res"},{"key":"3246_CR73","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.78810","volume":"11","author":"M Fan","year":"2022","unstructured":"Fan M, Lu W, Che J, et al. Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling. Elife. 2022;11:e78810.","journal-title":"Elife"},{"key":"3246_CR74","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/neuonc\/noac019","volume":"24","author":"RD Read","year":"2022","unstructured":"Read RD. Repurposing the drug verteporfin as anti-neoplastic therapy for glioblastoma. Neuro Oncol. 2022;24:708\u201310.","journal-title":"Neuro Oncol"},{"key":"3246_CR75","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1158\/2326-6066.CIR-19-0159","volume":"8","author":"J Liang","year":"2020","unstructured":"Liang J, Wang L, Wang C, et al. Verteporfin inhibits PD-L1 through autophagy and the STAT1\u2013IRF1\u2013TRIM28 signaling axis, exerting antitumor efficacy. Cancer Immunol Res. 2020;8:952\u201365.","journal-title":"Cancer Immunol Res"},{"key":"3246_CR76","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21946","volume":"8","author":"MH Kang","year":"2017","unstructured":"Kang MH, Jeong GS, Smoot DT, et al. Verteporfin inhibits gastric cancer cell growth by suppressing adhesion molecule FAT1. Oncotarget. 2017;8:98887.","journal-title":"Oncotarget"},{"key":"3246_CR77","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/mc.23307","volume":"60","author":"M Mickle","year":"2021","unstructured":"Mickle M, Adhikary G, Shrestha S, et al. VGLL4 inhibits YAP1\/TEAD signaling to suppress the epidermal squamous cell carcinoma cancer phenotype. Mol Carcinog. 2021;60:497\u2013507.","journal-title":"Mol Carcinog"},{"key":"3246_CR78","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.3390\/ijms25063381","volume":"25","author":"G Christodoulidis","year":"2024","unstructured":"Christodoulidis G, Koumarelas KE, Kouliou MN, et al. Gastric cancer in the era of epigenetics. Int J Mol Sci. 2024;25:3381.","journal-title":"Int J Mol Sci"},{"key":"3246_CR79","unstructured":"Berasain C, Arechederra M, Fern\u00e1ndez-Barrena MG, et al. Epigenetic mechanisms in gastric cancer: potential new therapeutic opportunities. 2020."},{"key":"3246_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-020-0218-z","volume":"9","author":"S Zhou","year":"2020","unstructured":"Zhou S, Zhang S, Wang L, et al. BET protein inhibitor JQ1 downregulates chromatin accessibility and suppresses metastasis of gastric cancer via inactivating RUNX2\/NID1 signaling. Oncogenesis. 2020;9:33.","journal-title":"Oncogenesis"},{"key":"3246_CR81","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1158\/2159-8290.CD-17-0605","volume":"8","author":"A Stathis","year":"2018","unstructured":"Stathis A, Bertoni F. BET proteins as targets for anticancer treatment. Cancer Discov. 2018;8:24\u201336.","journal-title":"Cancer Discov"},{"key":"3246_CR82","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4251\/wjgo.v14.i1.75","volume":"14","author":"HY Sun","year":"2022","unstructured":"Sun HY, Du ST, Li YY, et al. Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers. World J Gastrointest Oncol. 2022;14:75.","journal-title":"World J Gastrointest Oncol"},{"key":"3246_CR83","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41392-023-01647-6","volume":"8","author":"ZQ Wang","year":"2023","unstructured":"Wang ZQ, Zhang ZC, Wu YY, et al. Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy. Signal Transduct Target Ther. 2023;8:420.","journal-title":"Signal Transduct Target Ther"},{"key":"3246_CR84","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10555-025-10253-7","volume":"44","author":"A Suraweera","year":"2025","unstructured":"Suraweera A, O\u2019Byrne KJ, Richard DJ. Epigenetic drugs in cancer therapy. Cancer Metastasis Rev. 2025;44:37.","journal-title":"Cancer Metastasis Rev"},{"key":"3246_CR85","volume":"17","author":"L Lorenz","year":"2024","unstructured":"Lorenz L, Zenz T, Oliinyk D, et al. Vorinostat treatment of gastric cancer cells leads to ROS-induced cell inhibition and a complex pattern of molecular alterations in Nrf2-dependent genes. Pharm. 2024;17:1080.","journal-title":"Pharm"},{"key":"3246_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2025.118396","author":"YC Xu","year":"2025","unstructured":"Xu YC, Zhang Y, Xue YJ, et al. Discovery of hydroxamate derivatives as potent anti-gastric cancer agents via inducing oxidative stress and DNA damage. Bioorg Med Chem. 2025. https:\/\/doi.org\/10.1016\/j.bmc.2025.118396.","journal-title":"Bioorg Med Chem"},{"key":"3246_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215472","volume":"14","author":"A Badie","year":"2022","unstructured":"Badie A, Gaiddon C, Mellitzer G. Histone deacetylase functions in gastric cancer: therapeutic target? Cancers (Basel). 2022;14:5472.","journal-title":"Cancers (Basel)"},{"key":"3246_CR88","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1002\/ijc.32667","volume":"146","author":"J Giraud","year":"2020","unstructured":"Giraud J, Molina\u2010Castro S, Seeneevassen L, et al. Verteporfin targeting YAP1\/TAZ\u2010TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells. Int J Cancer. 2020;146:2255\u201367.","journal-title":"Int J Cancer"},{"key":"3246_CR89","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1158\/1538-7445.AM2023-4491","volume":"83","author":"A Liang","year":"2023","unstructured":"Liang A, Dong S, Liu G, et al. TY-0584: A potent, orally available small molecule YAP\/TEAD inhibitor, exhibits anti-tumor effects in vitro and in vivo. Cancer Res. 2023;83:4491.","journal-title":"Cancer Res"},{"key":"3246_CR90","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13046-023-02615-2","volume":"42","author":"M Feng","year":"2023","unstructured":"Feng M, Xu H, Zhou W, et al. The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma. J Exp Clin Cancer Res. 2023;42:44.","journal-title":"J Exp Clin Cancer Res"},{"key":"3246_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2022.106328","volume":"131","author":"J Song","year":"2023","unstructured":"Song J, Liu X, Zhang YF, et al. The dual FAK-HDAC inhibitor MY-1259 displays potent activities in gastric cancers in vitro and in vivo. Bioorg Chem. 2023;131:106328.","journal-title":"Bioorg Chem"},{"key":"3246_CR92","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41434-020-00201-1","volume":"29","author":"XY Zhang","year":"2022","unstructured":"Zhang XY, Zhuang HW, Wang J, et al. Long noncoding RNA CA3-AS1 suppresses gastric cancer migration and invasion by sponging miR-93-5p and targeting BTG3. Gene Ther. 2022;29:566\u201374.","journal-title":"Gene Ther"},{"key":"3246_CR93","doi-asserted-by":"publisher","DOI":"10.1177\/10732748241293699","volume":"31","author":"L Shen","year":"2024","unstructured":"Shen L, Li Y, Huang H, et al. HER2 in gastric cancer: a comprehensive analysis combining meta-analysis and DCE-MRI radiomics. Cancer Control. 2024;31:10732748241293700.","journal-title":"Cancer Control"},{"key":"3246_CR94","doi-asserted-by":"crossref","unstructured":"Gentile G, Gerosa R, de Azambuja E, et al. 20th anniversary of adjuvant trastuzumab: reflections on a breakthrough moment. Ann Oncol. 2025.","DOI":"10.1016\/j.annonc.2025.12.002"},{"key":"3246_CR95","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-024-01508-3","volume":"27","author":"J Qiao","year":"2024","unstructured":"Qiao J, Feng M, Zhou W, et al. YAP inhibition overcomes adaptive resistance in HER2-positive gastric cancer treated with trastuzumab via the AKT\/mTOR and ERK\/mTOR axis. Gastric Cancer. 2024;27:785.","journal-title":"Gastric Cancer"},{"key":"3246_CR96","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1038\/s41388-018-0204-5","volume":"37","author":"J Shi","year":"2018","unstructured":"Shi J, Li F, Yao X, et al. The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition. Oncogene. 2018;37:3022\u201338.","journal-title":"Oncogene"},{"key":"3246_CR97","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1634\/theoncologist.2017-0379","volume":"23","author":"A D\u00edaz\u2010Serrano","year":"2018","unstructured":"D\u00edaz\u2010Serrano A, Angulo B, Dominguez C, et al. Genomic profiling of HER2\u2010positive gastric cancer: PI3K\/Akt\/mTOR pathway as predictor of outcomes in HER2\u2010positive advanced gastric cancer treated with trastuzumab. Oncologist. 2018;23:1092\u2013102.","journal-title":"Oncologist"},{"key":"3246_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1285343","volume":"14","author":"K Liu","year":"2023","unstructured":"Liu K, Yuan S, Wang C, et al. Resistance to immune checkpoint inhibitors in gastric cancer. Front Pharmacol. 2023;14:1285343.","journal-title":"Front Pharmacol"},{"key":"3246_CR99","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.semcancer.2019.11.011","volume":"65","author":"Y Kobayashi","year":"2020","unstructured":"Kobayashi Y, Lim SO, Yamaguchi H. Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer. Semin Cancer Biol Elsevier. 2020;65:51\u201364.","journal-title":"Semin Cancer Biol Elsevier"},{"key":"3246_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110586","volume":"122","author":"C Liu","year":"2023","unstructured":"Liu C, Song Y, Li D, et al. Regulation of the tumor immune microenvironment by the Hippo pathway: implications for cancer immunotherapy. Int Immunopharmacol. 2023;122:110586.","journal-title":"Int Immunopharmacol"},{"key":"3246_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1377722","volume":"15","author":"Y Gao","year":"2024","unstructured":"Gao Y, Gong Y, Lu J, et al. Targeting YAP1 to improve the efficacy of immune checkpoint inhibitors in liver cancer: mechanism and strategy. Front Immunol. 2024;15:1377722.","journal-title":"Front Immunol"},{"key":"3246_CR102","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.2217\/fon-2019-0035","volume":"15","author":"Z Tang","year":"2019","unstructured":"Tang Z, Ma Q, Wang L, et al. A brief review: some compounds targeting YAP against malignancies. Future Oncol. 2019;15:1535\u201343.","journal-title":"Future Oncol"},{"key":"3246_CR103","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3390\/cells10010184","volume":"10","author":"K Masliantsev","year":"2021","unstructured":"Masliantsev K, Karayan-Tapon L, Guichet PO. Hippo signaling pathway in gliomas. Cells. 2021;10:184.","journal-title":"Cells"},{"key":"3246_CR104","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13046-023-02704-2","volume":"42","author":"J Luo","year":"2023","unstructured":"Luo J, Deng L, Zou H, et al. New insights into the ambivalent role of YAP\/TAZ in human cancers. J Exp Clin Cancer Res. 2023;42:130.","journal-title":"J Exp Clin Cancer Res"},{"key":"3246_CR105","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1158\/0008-5472.CAN-19-3803","volume":"80","author":"T Uchihara","year":"2020","unstructured":"Uchihara T, Miyake K, Yonemura A, et al. Extracellular vesicles from cancer-associated fibroblasts containing annexin A6 induces FAK-YAP activation by stabilizing \u03b21 integrin, enhancing drug resistance. Cancer Res. 2020;80:3222\u201335.","journal-title":"Cancer Res"},{"key":"3246_CR106","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3390\/cancers13020318","volume":"13","author":"R Zeng","year":"2021","unstructured":"Zeng R, Dong J. The hippo signaling pathway in drug resistance in cancer. Cancers (Basel). 2021;13:318.","journal-title":"Cancers (Basel)"},{"key":"3246_CR107","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.ccell.2021.06.016","volume":"39","author":"JD Pearson","year":"2021","unstructured":"Pearson JD, Huang K, Pacal M, et al. Binary pan-cancer classes with distinct vulnerabilities defined by pro-or anti-cancer YAP\/TEAD activity. Cancer Cell. 2021;39:1115\u201334.","journal-title":"Cancer Cell"},{"key":"3246_CR108","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s13205-024-04186-1","volume":"15","author":"H Fatima","year":"2025","unstructured":"Fatima H, Singh D, Muhammad H, et al. Improving the use of CRISPR\/Cas9 gene editing machinery as a cancer therapeutic tool with the help of nanomedicine. 3 Biotech. 2025;15:17.","journal-title":"3 Biotech"},{"key":"3246_CR109","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13062-023-00449-8","volume":"19","author":"L Li","year":"2024","unstructured":"Li L, Tang J, Cao B, et al. GPR137 inactivates Hippo signaling to promote gastric cancer cell malignancy. Biol Direct. 2024;19:3.","journal-title":"Biol Direct"},{"key":"3246_CR110","doi-asserted-by":"publisher","first-page":"23","DOI":"10.34133\/bmr.0023","volume":"28","author":"M Li","year":"2024","unstructured":"Li M, Chen F, Yang Q, et al. Biomaterial-based CRISPR\/Cas9 delivery systems for tumor treatment. Biomater Res. 2024;28:23.","journal-title":"Biomater Res"},{"key":"3246_CR111","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.3390\/genes13112029","volume":"13","author":"RS Almeida","year":"2022","unstructured":"Almeida RS, Wisnieski F, Takao Real Karia B, et al. CRISPR\/Cas9 genome-editing technology and potential clinical application in gastric cancer. Genes (Basel). 2022;13:2029.","journal-title":"Genes (Basel)"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03246-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03246-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03246-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T13:03:52Z","timestamp":1775653432000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03246-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":111,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["3246"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03246-1","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This is a review article. No ethical approval is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable as no human subjects were involved in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable as no human subjects were involved in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"147"}}